LAUSR

Many enterocins were produced from the lactic acid bacteria, Enterococcus faecalis, they belonged to different types of bacteriocins and have different characteristics. The present study aimed to search for another enterocin and test its ability to inhibit Klebsiella pneumoniae biofilm as compared with the most effective antibacterial agent. E. faecalis isolates were isolated from stools of breastfeeding babies. Klebsiella pneumoniae isolates were from urinary tract infections and urinary catheters. K. pneumoniae isolates showed biofilm formation potential and multidrug resistance phenotype but amikacin was the most effective one. Enterocin production by gene harboring E. faecalis was screened, then enterocin was purified, characterized, and antibacterial activity and MIC of enterocin were determined. Produced enterocin has characteristics differ from other discovered enterocins. Furthermore, the crude and purified enterocin of E. faecalis possess significant antibacterial activity against K. pneumoniae isolates as compare with control (p < 0.05), and antibiofilm activity of enterocin was stronger than the antibiofilm activity of amikacin (P < 0.05), as well as the enterocin, was potent than the amikacin in preventing the formation of biofilm on the catheter. In conclusion, a novel enterocin was produced from Enterococcus faecalis (enterocin GLHM) is proteinous bacteriocin, relatively heat-stable and have full activity at neutral pH and was belong to type II bacteriocin. Enterocin GLHM have anti-K. pneumoniae and anti-K. pneumoniae biofilm significantly better than amikacin.